title: Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis.
abstract: Haemorrhage is a frequent manifestation of amyloidosis. We performed a retrospective clinical analysis of 337 patients with systemic immunoglobulin light-chain (AL)-amyloidosis, in whom whole-body serum amyloid P component (SAP) scintigraphy and a clotting screen had been performed. Abnormal bleeding was noted in 94 cases (28%), and the coagulation screen was abnormal in 172 cases (51%). The most common abnormalities were prolongation of the thrombin time (TT; 108 cases, 32%) and the prothrombin time (PT; 82 cases, 24%). In multivariate analysis, a prolonged PT was the only coagulation abnormality associated with abnormal bleeding (P = 0.0012), but this was independent of the whole-body amyloid load. Prolongation of the TT was associated with hepatic amyloid infiltration (P < 0.00001), with proteinuria (P < 0.001) and low serum albumin (P < 0.00001). In 154 patients who were studied further, subnormal factor X activity (FX:C) was found in 22 cases (14%). In cases with subnormal FX:C, the corresponding factor X antigen (FX:Ag) measurements were consistently higher (median FX:Ag/FX:C 2.5, range 0.81-9.25, n = 16) than cases with normal FX:C (median FX:Ag/FX:C 0.96, range 0.65-1.29, n = 28, P < 0.0001). No evidence was found of an FX inhibitor. Of the 48/154 (31%) cases with a prolonged TT, the reptilase time was also prolonged in 38/48 cases (79%). These data show that haemorrhage and abnormal coagulation are common in AL-amyloidosis and are multifactorial in origin. We provide evidence suggesting that hepatic amyloid infiltration and nephrotic syndrome are determinants of the TT. In most patients, prolongation of the PT was explained by reduction in FX:C, but this was not wholly explained by a reduction in FX:Ag.
authors.affiliation: Department of Haematology, Imperial College School of Medicine, Hammersmith Hospital, London, UK.
authors.forename: A D
authors.initials: AD
authors.lastname: Mumford
authors.forename: J
authors.initials: J
authors.lastname: O'Donnell
authors.forename: J D
authors.initials: JD
authors.lastname: Gillmore
authors.forename: R A
authors.initials: RA
authors.lastname: Manning
authors.forename: P N
authors.initials: PN
authors.lastname: Hawkins
authors.forename: M
authors.initials: M
authors.lastname: Laffan
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000686:Amyloidosis / Q000097:blood / Q000150:complications*; D001778:Blood Coagulation Disorders / Q000097:blood / Q000209:etiology*; D005171:Factor X Deficiency / Q000150:complications; D005260:Female; D006470:Hemorrhage / Q000097:blood / Q000209:etiology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009404:Nephrotic Syndrome / Q000209:etiology; D011517:Prothrombin Time; D012189:Retrospective Studies; D012307:Risk Factors; D013918:Thrombin Time